Home › Bladder Cancer › Wisconsin › Oshkosh
Bladder Cancer clinical trials in Oshkosh, WI
3 studies for Bladder Cancer are looking for participants at sites in and around Oshkosh (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- ThedaCare Cancer Care - Oshkosh, Oshkosh
- Vince Lombardi Cancer Clinic - Oshkosh, Oshkosh
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
RecruitingPhase 2
- Ascension Northeast Wisconsin-Mercy Hospital-Oshkosh, Oshkosh
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RecruitingPhase 2
- Vince Lombardi Cancer Clinic - Oshkosh, Oshkosh
About Bladder Cancer
Bladder cancer symptoms range from lower back pain to blood in your urine. Read about important risk factors and find a list of treatments available
More about Bladder Cancer on MedlinePlus
Bladder Cancer trials in other cities
- New York City, NY35 studies
- Nashville, TN31 studies
- Houston, TX31 studies
- Dallas, TX27 studies
- Boston, MA26 studies
- Washington, DC26 studies
- Los Angeles, CA24 studies
- Baltimore, MD24 studies
- St. Louis, MO22 studies
- Philadelphia, PA21 studies
- Seattle, WA21 studies
- Edison, NJ21 studies
Other studies in Oshkosh
- Lung Cancer8 studies
- Colorectal Cancer6 studies
- Non-Small Cell Lung Cancer6 studies
- Breast Cancer5 studies
- Kidney Cancer (Renal Cell Carcinoma)4 studies
- Prostate Cancer4 studies
- Cancer (all types)3 studies
- Head and Neck Squamous Cell Carcinoma3 studies
- Ovarian Cancer3 studies
- Pancreatic Cancer3 studies
- Colon Cancer3 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.